Table 2 Clinical and pathologic characteristics of the 202 study patients
Overall | High GNRI (≥ 98) | Low GNRI (< 98) | P value | |
|---|---|---|---|---|
Case n (%) | 202 | 116 (57.4%) | 86 (42.6%) | |
Age, years | 68.54 ± 11.02 | 66.51 ± 9.89 | 71.28 ± 11.90 | 0.001 |
Female (%) | 68.3% | 73.3% | 61.6% | 0.093 |
BMI, kg/m2 | 22.87 ± 3.29 | 24.23 ± 3.05 | 21.03 ± 2.66 | < 0.001 |
Hemoglobin mean, g/L | 124.94 ± 17.97 | 129.18 ± 16.62 | 119.21 ± 18.22 | < 0.001 |
Serum albumin mean, g/L | 38.30 ± 5.18 | 41.44 ± 3.11 | 34.07 ± 4.32 | < 0.001 |
NLR | < 0.001 | |||
< 2.6 | 61.4% | 75.0% | 43.0% | |
≥ 2.6 | 38.6% | 25.0% | 57.0% | |
Serum CA19-9 (U/mL) > 37 | 0.017 | |||
No | 58.9% | 67.0% | 47.9% | |
Yes | 41.1% | 33.0% | 52.1% | |
Serum CEA level (ng/mL) > 5 | 0.145 | |||
No | 77.5% | 81.4% | 71.8% | |
Yes | 22.5% | 18.6% | 28.2% | |
T (%) | 0.280 | |||
I–II | 34.9% | 38.5% | 30.0% | |
III–IV | 65.1% | 61.5% | 70.0% | |
Gallstones (%) | 0.012 | |||
No | 39.9% | 47.7% | 29.8% | |
Yes | 60.1% | 52.3% | 70.2% | |
Tumor size (cm) > 3 (%) | 0.408 | |||
No | 53.2% | 56.4% | 48.3% | |
Yes | 46.8% | 43.6% | 51.7% | |
Differentiation of GBC (%) | 0.042 | |||
Poor/unknown | 37.4% | 32.0% | 45.1% | |
Well/moderate | 62.6% | 68.0% | 54.9% | |
TNM stage (%) | 0.354 | |||
I–II | 30.5% | 33.3% | 26.7% | |
III–IV | 69;.5 | 66.7% | 73.3% | |
Lymph node metastases (%) | 0.610 | |||
No | 75.3% | 77.1% | 72.8% | |
Yes | 24.7% | 22.9% | 27.2% |